Neurona’s lead asset, rezanecel, under phase l/ll investigation for drug-resistant mesial temporal lobe epilepsy1,2, builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy. Acquisition accelerates UCB’s entry into next-generation disease-modifying therapies and cell therapies.
Elementis plc (London) has completed the sale of its pharmaceutical manufacturing business to Associated British Foods (ABF). Under the terms of the Transaction, the business was sold for an enterprise value of €34.3 million (equivalent to around $39.8 million), with net cash proceeds after transaction costs of approximately €30 million.
One company explicitly justifies this with the German government’s savings plans in the healthcare sector, while the other refers to this, among other things. In the case of the US company, this involves a sum in the billions that was actually intended for a new site in Alzey in Rhineland-Palatinate, while the German company is talking about a high three-digit million sum.
